Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 5Prostatic Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Ovarian Neoplasms 3Lung Neoplasms 3Rectal Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2Kidney Neoplasms 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Staphylococcal Infections 1Sarcoma 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neoplasms 1Neurofibromatoses 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mesothelioma 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × NIH × Endometrial Serous Adenocarcinoma × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡